Strategies to Improve the Performance of Antibody Drug Conjugates

On October 24, 2018 8:00 (GMT-7)
Live Webinar
English

Improving Therapeutic index and Minimizing On and Off-target Toxicities of Highly Potent Antibody Drug Conjugates

Antibody–drug conjugates (ADCs) generally refer to tumor antigen targeted antibodies incorporating cytotoxic anticancer drugs through highly stable linkers. Since the concept of a “magic bullet” for targeted drugs was coined, the approvals of brentuximab anti-CD33-ADC vedotin (in 2011) anti-HER2 ADC trastuzumab emtansine (in 2013) and Mylotarg CD33-Calicheamicin ADC (in 2017) have revolutionized the development of ADCs with over 250 clinical trials and more than 60 distinct ADC molecules currently in development. Despite this revolutionary growth, the low therapeutic index or limited safety window of ADCs has posed a major challenge in achieving the success in treatment of solid tumors.  

Join our expert speaker for this complimentary webinar and learn about strategies for decreasing toxicities, increasing tumor cytotoxicity and overall improving the therapeutic index of ADCs.

Key learning objectives include:

  • Tumor intrinsic and warhead associated challenges in improving the TI
  • Why antibody characteristics are more important than first realized
  • Optimization of warhead potency
  • Pros and cons of site-specific conjugation and linkers
  • Impact of ADC disposition on TI
  • Dosing schedule and mitigation of toxicities
  • Translational medicine approaches to improve TI

E-SEMINAR: STRATEGIES TO IMPROVE THE PERFORMANCE OF ANTIBODY DRUG CONJUGATES
BIOVIA Improve Therapeutic index > Rakesh Dixit > Dassault Systèmes®

About the Presenter

Rakesh DIXIT, PhD, DABT

Vice President, R&D; Global Head, Translational Sciences-Biologics

Safety Assessment

MedImmune

Dr. Rakesh DIXIT has more than 30 years of experience in biopharmaceutical drug industry, including Merck, Johnson & Johnson and Medimmune (AstraZeneca). At his current role as the Vice President of R &D and Global Head of Safety Assessment-Translational Sciences, in Medimmune, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines.